India Plans Crackdown On Drug Maker Unfair Margins
This article was originally published in PharmAsia News
Drug makers who charge wholesalers and pharmacists more than what is considered the government's "fair margin" could be fined the difference. The ministry of chemicals and fertilizers is considering a plan to make every company involved in the chain of getting a drug from manufacturer to patient to disclose the margins pharmaceutical firms offer outside of price controls at each level. The ministry estimates 75 percent of the retail market consists of such drugs. The plan also includes creation of trade margin caps as a percentage of retail prices. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.